06.08.2010 • News

Huntsman Posts Better-Than-Expected Q2 Profit

Chemicals maker Huntsman posted a higher-than-expected quarterly profit on Thursday as sales jumped across its units, pushing shares up 4.7% in premarket trading. For the period that ended June 30, the company posted net income of $114 million, or 47 cents per share, compared with $406 million, or $1.51 per share, in the year-ago period.

The year-ago results include a settlement with two banks over a botched sale of Huntsman to a private equity firm. Excluding one-time items, the company posted a profit of 31 cents per share.

Analysts expected earnings of 8 cents per share, according to Thomson Reuters I/B/E/S. Revenue rose 27% to $2.34 billion. Analysts expected revenue of $2.19 billion.

Huntsman, based in The Woodlands, Texas, said sales in its polyurethane business rose 34% and pricing increased 11%. Polyurethane is used to construct a wide range of products, including foam insulation and Spandex. Its shares rose 48 cents, or 4.7%, to $10.75 in premarket trading. The stock has traded between $6.10 and $14.25 in the past 52 weeks.

Company

Huntsman

Everslaan 45
3078 Everberg
Belgium

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read